Brian Druker: Imatinib as a Paradigm of Targeted Cancer Therapies

I. Imatinib (Gleevec): A Targeted Cancer Therapy
II. Imatinib Resistance and Other Diseases Targeted by Imatinib
III. Extending the Imatinib Paradigm

Part I: Imatinib (Gleevec): A Targeted Cancer Therapy

Download: This VideoSubtitled Videos: English
Resources: Transcript(.txt)(.xls)Related Articles
Trouble Viewing? Try it on iTunes.Report a problem.

Lecture Overview
Imatinib (Gleevec) has become a paradigm for targeted cancer therapies. The first part of this lecture will describe the clinical features and the molecular pathogenesis of the disease for which imatinib was developed, chronic myeloid leukemia (CML). This overview will trace the history of the identification of the target of imatinib, BCR-ABL. The preclinical development of the BCR-ABL kinase inhibitor, imatinib and highly successful clinical trials of this agent for patients with CML will be reviewed along with the most up-to-date follow-up on these studies.  More >>

Speaker Bio
Dr. Brian Druker is an Investigator of the Howard Hughes Medical Institute, Director of the Oregon Health & Science University (OHSU) Cancer Institute, and JELD-WEN Chair of Leukemia Research at OHSU. Upon graduating from the University of California, San Diego School of Medicine in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital, Washington School of Medicine in St. Louis, Missouri. He then trained in oncology at Harvard’s Dana-Farber Cancer Institute.   More >>

Related Talks

Speak Your Mind

7ads6x98y